Australia - English - Department of Health (Therapeutic Goods Administration)

happy natural living pty ltd - alpha lipoic acid, quantity: 50 mg; selenomethionine, quantity: 18.6 microgram (equivalent: selenium, qty 7.5 microgram); brassica oleracea var. italica, quantity: 7.3 mg (equivalent: brassica oleracea var. italica, qty 87.6 mg); arctium lappa, quantity: 27.5 mg (equivalent: arctium lappa, qty 275 mg); choline bitartrate, quantity: 85 mg; glutathione, quantity: 25 mg; ascorbic acid, quantity: 25 mg; cynara scolymus, quantity: 15 mg (equivalent: cynara scolymus, qty 750 mg); silybum marianum, quantity: 13.4 mg (equivalent: silybum marianum, qty 938 mg) - capsule, hard - excipient ingredients: rice bran oil; microcrystalline cellulose; silicon dioxide; citrus bioflavonoids extract; purified water; oryza sativa; hypromellose; acacia; sunflower oil - antioxidant/reduce free radicals formed in the body ; maintain/support natural liver cleansing/detoxification processes ; traditionally used in western herbal medicine to maintain/support waste elimination via the mucous membranes ; traditionally used in western herbal medicine to aids/assists excretion of metabolic waste products ; traditionally used in western herbal medicine to maintain/support waste elimination via the skin ; traditionally used in western herbal medicine to aids/assists body waste elimination ; traditionally used in western herbal medicine to maintain/support body waste elimination ; maintain/support general health and wellbeing ; traditionally used in western herbal medicine to hepatoprotectant/protect the liver ; traditionally used in western herbal medicine to promote bile flow from liver/chloretic ; traditionally used in western herbal medicine to maintain/support healthy liver function ; maintain/support healthy liver function ; maintain/support liver health ; maintain/support oestrogen hormone levels

Australia - English - Department of Health (Therapeutic Goods Administration)

uncommon collective pty ltd - alpha lipoic acid, quantity: 50 mg; selenomethionine, quantity: 18.6 microgram (equivalent: selenium, qty 7.5 microgram); brassica oleracea var. italica, quantity: 7.3 mg (equivalent: brassica oleracea var. italica, qty 87.6 mg); arctium lappa, quantity: 27.5 mg (equivalent: arctium lappa, qty 275 mg); choline bitartrate, quantity: 85 mg; glutathione, quantity: 25 mg; ascorbic acid, quantity: 25 mg; cynara scolymus, quantity: 15 mg (equivalent: cynara scolymus, qty 750 mg); silybum marianum, quantity: 13.4 mg (equivalent: silybum marianum, qty 938 mg) - capsule, hard - excipient ingredients: rice bran oil; microcrystalline cellulose; silicon dioxide; citrus bioflavonoids extract; purified water; hypromellose; calcium hydrogen phosphate dihydrate; acacia; sunflower oil; oryza sativa - antioxidant/reduce free radicals formed in the body ; maintain/support natural liver cleansing/detoxification processes ; traditionally used in western herbal medicine to maintain/support waste elimination via the mucous membranes ; traditionally used in western herbal medicine to aids/assists excretion of metabolic waste products ; traditionally used in western herbal medicine to maintain/support waste elimination via the skin ; traditionally used in western herbal medicine to aids/assists body waste elimination ; traditionally used in western herbal medicine to maintain/support body waste elimination ; maintain/support general health and wellbeing ; traditionally used in western herbal medicine to hepatoprotectant/protect the liver ; traditionally used in western herbal medicine to promote bile flow from liver/chloretic ; traditionally used in western herbal medicine to maintain/support healthy liver function ; maintain/support healthy liver function ; maintain/support liver health ; maintain/support oestrogen hormone levels

Australia - English - Department of Health (Therapeutic Goods Administration)

happy natural living pty ltd - glutathione, quantity: 25 mg; choline bitartrate, quantity: 85.09 mg; ascorbic acid, quantity: 25 mg; cynara scolymus, quantity: 7.5 mg (equivalent: cynara scolymus, qty 750 mg); arctium lappa, quantity: 27.5 mg (equivalent: arctium lappa, qty 275 mg); alpha lipoic acid, quantity: 50 mg; brassica oleracea var. italica, quantity: 12.5 mg (equivalent: brassica oleracea var. italica, qty 3.75 g); selenomethionine, quantity: 18.6 microgram (equivalent: selenium, qty 7.5 microgram); silybum marianum, quantity: 13.39 mg (equivalent: silybum marianum, qty 937.5 mg) - capsule, hard - excipient ingredients: citrus bioflavonoids extract; hypromellose; silicon dioxide; purified water; ethylcellulose; sorbitol; maltodextrin; bambusa breviflora; rice bran oil; microcrystalline cellulose; acacia; sunflower oil; oryza sativa - antioxidant/reduce free radicals formed in the body ; maintain/support natural liver cleansing/detoxification processes ; traditionally used in western herbal medicine to maintain/support waste elimination via the mucous membranes ; traditionally used in western herbal medicine to aids/assists excretion of metabolic waste products ; traditionally used in western herbal medicine to maintain/support waste elimination via the skin ; traditionally used in western herbal medicine to aids/assists body waste elimination ; traditionally used in western herbal medicine to maintain/support body waste elimination ; maintain/support general health and wellbeing ; traditionally used in western herbal medicine to hepatoprotectant/protect the liver ; traditionally used in western herbal medicine to promote bile flow from liver/chloretic ; traditionally used in western herbal medicine to maintain/support healthy liver function ; maintain/support healthy liver function ; maintain/support liver health ; maintain/support oestrogen hormone levels

Australia - English - Department of Health (Therapeutic Goods Administration)

uncommon collective pty ltd - glutathione, quantity: 25 mg; choline bitartrate, quantity: 85.09 mg (equivalent: choline, qty 35 mg); ascorbic acid, quantity: 25 mg; cynara scolymus, quantity: 7.5 mg (equivalent: cynara scolymus, qty 750 mg); arctium lappa, quantity: 27.5 mg (equivalent: arctium lappa, qty 275 mg); alpha lipoic acid, quantity: 50 mg; brassica oleracea var. italica, quantity: 12.5 mg (equivalent: brassica oleracea var. italica, qty 3.75 g); selenomethionine, quantity: 18.6 microgram (equivalent: selenium, qty 7.5 microgram); silybum marianum, quantity: 13.39 mg (equivalent: silybum marianum, qty 937.5 mg) - capsule, hard - excipient ingredients: citrus bioflavonoids extract; hypromellose; rice bran oil; microcrystalline cellulose; silicon dioxide; purified water; maltodextrin; ethylcellulose; sorbitol; bambusa breviflora; acacia; sunflower oil; oryza sativa - antioxidant/reduce free radicals formed in the body ; maintain/support natural liver cleansing/detoxification processes ; traditionally used in western herbal medicine to maintain/support waste elimination via the mucous membranes ; traditionally used in western herbal medicine to aids/assists excretion of metabolic waste products ; traditionally used in western herbal medicine to maintain/support waste elimination via the skin ; traditionally used in western herbal medicine to aids/assists body waste elimination ; traditionally used in western herbal medicine to maintain/support body waste elimination ; maintain/support general health and wellbeing ; traditionally used in western herbal medicine to hepatoprotectant/protect the liver ; traditionally used in western herbal medicine to promote bile flow from liver/chloretic ; traditionally used in western herbal medicine to maintain/support healthy liver function ; maintain/support healthy liver function ; maintain/support liver health ; maintain/support oestrogen hormone levels

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.91 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 151.92 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - estrogens conjugated - coated tablet - estrogens conjugated 1.25 mg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - estrogens conjugated - coated tablet - estrogens conjugated 0.625 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.625 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; carnauba wax; sucrose; hypromellose; lactose monohydrate; macrogol 400; hyprolose; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; allura red ac aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1 premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.625mg - conjugated estrogens 0.625mg - estrogens